76/100 B+ · Elevated risk
No major risk flags in the public sources we cover Indicative TraceComp estimate from public sources — an automated indicator, not a credit decision, a completed due-diligence check, or a guarantee. Verify against the official register.

ℹ️ No matches surfaced in the limited public sources we cover (sanctions, screening, insolvency, control). This is an automated indicator — not an exhaustive check, a credit decision, or a guarantee, and absence of a match does not mean none exists. Verify against the official register.

Think this is wrong? This is an automated estimate — request a human review or correction.

TRAXENS

Active Simplified joint-stock company (SAS) Other professional & technical Active for 14 years

Simplified joint-stock company (SAS) · RC 750626871 · Active since 2012

B+

Overview

TRAXENS is a simplified joint-stock company (sas) registered in France, since 2012. The company operates in the other professional & technical sector. With reported revenue of 7.9M EUR in 2024. Its TraceComp score of 76 (B+) indicates solid fundamentals and low apparent risk. With 14 years of operations, the company has an established track record in its market.

Company Information

Registration Number
750626871
Legal Form
Simplified joint-stock company (SAS)
Registered
2012-03-01

Financial Profile

Latest filed accounts: FY 2024

Revenue (2024) 7,888,551 EUR
Net Income -2,971,978 EUR
Total Assets 9,562,802 EUR
Altman Z 0.42 distress

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

EU Funding

EU-funded innovation. Participated in 2 EU research projects, receiving €598,197 in EU contributions (CORDIS — Horizon Europe / Horizon 2020).

Source: CORDIS (EU Open Data, CC-BY). Cumulative EC contribution across the company’s projects.

Patent Portfolio

Active patent holder. 3 patents · 3 active · 3 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Net loss reported in FY 2024
  • Altman Z-Score in the distress zone — elevated insolvency risk on the model

Data Sources & Freshness

Data sourced from: bulk register.